Published in Invest New Drugs on January 19, 2010
Concise route to a series of novel 3-(tetrazol-5-yl)quinoxalin-2(1H)-ones. Tetrahedron Lett (2012) 0.88
Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor. Invest New Drugs (2010) 0.76
CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev (1999) 24.83
Cancer cell cycles. Science (1996) 21.29
P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol (2000) 5.64
A decade of CDK5. Nat Rev Mol Cell Biol (2001) 5.24
The Pezcoller lecture: cancer cell cycles revisited. Cancer Res (2000) 5.08
Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell (1999) 4.94
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet (2003) 4.74
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell (2004) 4.39
Cdk2 knockout mice are viable. Curr Biol (2003) 3.92
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res (1996) 3.89
How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell (1999) 3.34
Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol (1999) 3.06
Regulation of transcription elongation by phosphorylation. Biochim Biophys Acta (2002) 2.41
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood (2008) 2.22
Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci (2002) 1.82
RB kinases and RB-binding proteins: new points of view. Trends Biochem Sci (1997) 1.73
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
Development of cell-cycle inhibitors for cancer therapy. Curr Oncol (2009) 1.57
Cyclins and cyclin-dependent kinases: theme and variations. Adv Cancer Res (1995) 1.29
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs (2004) 1.17
Cyclin-dependent kinase 5 promotes insulin exocytosis. J Biol Chem (2001) 1.15
A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs (2007) 1.11
Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica (2006) 1.05
A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2005) 0.97
Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. Bioorg Med Chem Lett (2006) 0.93
CDK9 (PITALRE): a multifunctional cdc2-related kinase. J Cell Physiol (1998) 0.90
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther (2010) 5.24
Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol (2006) 4.07
MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther (2010) 2.68
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther (2009) 2.50
Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem (2003) 2.36
Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. Immunity (2004) 2.29
CCL17 and IL-10 as effectors that enable alternatively activated macrophages to inhibit the generation of classically activated macrophages. J Immunol (2004) 2.25
Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int Immunol (2004) 1.91
A functional [NiFe]hydrogenase mimic that catalyzes electron and hydride transfer from H2. Science (2013) 1.63
Influence of systemic inflammatory response syndrome on host resistance against bacterial infections. Crit Care Med (2004) 1.59
Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer (2004) 1.52
MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther (2010) 1.48
Pivotal advance: glycyrrhizin restores the impaired production of beta-defensins in tissues surrounding the burn area and improves the resistance of burn mice to Pseudomonas aeruginosa wound infection. J Leukoc Biol (2009) 1.46
Cryptococcal encephalitis in thermally injured mice is accelerated by type 2 T-cell responses. Crit Care Med (2002) 1.39
In vitro transdifferentiation of mature hepatocytes into insulin-producing cells. Endocr J (2006) 1.39
The selective continued linkage of centromeres from mitosis to interphase in the absence of mammalian separase. J Cell Biol (2006) 1.39
Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res (2006) 1.32
Base excision repair as a therapeutic target in colon cancer. Clin Cancer Res (2002) 1.25
A protein associated with toll-like receptor 4 (PRAT4A) regulates cell surface expression of TLR4. J Immunol (2006) 1.21
The ATM-related Tel1 protein of Saccharomyces cerevisiae controls a checkpoint response following phleomycin treatment. Nucleic Acids Res (2003) 1.20
Structural basis of human p70 ribosomal S6 kinase-1 regulation by activation loop phosphorylation. J Biol Chem (2009) 1.17
Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer (2009) 1.11
Preferences for phosphorylation sites in the retinoblastoma protein of D-type cyclin-dependent kinases, Cdk4 and Cdk6, in vitro. J Biochem (2005) 1.11
Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases. Curr Top Med Chem (2005) 1.09
A membrane-bound archaeal Lon protease displays ATP-independent proteolytic activity towards unfolded proteins and ATP-dependent activity for folded proteins. J Bacteriol (2002) 1.05
Vitamin D3 up-regulated protein-1 regulates collagen expression in mesangial cells. Kidney Int (2003) 1.04
Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors. Protein Sci (2007) 1.01
Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity. J Med Chem (2006) 1.01
Aryl hydrocarbon receptor plays a significant role in mediating airborne particulate-induced carcinogenesis in mice. Environ Sci Technol (2007) 1.01
Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. Gastroenterology (2009) 0.99
Identification of dicarboxylate carrier Slc25a10 as malate transporter in de novo fatty acid synthesis. J Biol Chem (2005) 0.98
A molecule that is associated with Toll-like receptor 4 and regulates its cell surface expression. Biochem Biophys Res Commun (2005) 0.97
Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc Natl Acad Sci U S A (2006) 0.95
An essential role of macrophage inflammatory protein 1alpha/CCL3 on the expression of host's innate immunities against infectious complications. J Leukoc Biol (2002) 0.94
Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. J Clin Invest (2002) 0.94
Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation. Curr Genomics (2008) 0.91
Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling. Cancer Res (2009) 0.91
DNA repair and cancer: lessons from mutant mouse models. Cancer Sci (2004) 0.90
Cooperative role of macrophages and neutrophils in host Antiprotozoan resistance in mice acutely infected with Cryptosporidium parvum. Infect Immun (2008) 0.90
Role of polymorphonuclear neutrophils on infectious complications stemming from Enterococcus faecalis oral infection in thermally injured mice. J Immunol (2008) 0.89
Enterococcus faecalis translocation in mice with severe burn injury: a pathogenic role of CCL2 and alternatively activated macrophages (M2aMphi and M2cMphi). J Leukoc Biol (2009) 0.89
Structures of the PKC-iota kinase domain in its ATP-bound and apo forms reveal defined structures of residues 533-551 in the C-terminal tail and their roles in ATP binding. Acta Crystallogr D Biol Crystallogr (2010) 0.89
Effectiveness of the timing principle with high-dose rocuronium during rapid sequence induction with lidocaine, remifentanil and propofol. J Anesth (2010) 0.89
Inhibition of p70S6K2 down-regulates Hedgehog/GLI pathway in non-small cell lung cancer cell lines. Mol Cancer (2009) 0.88
Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets. Curr Mol Med (2008) 0.88
Lack of Th17 cell generation in patients with severe burn injuries. J Immunol (2011) 0.87
Glycyrrhizin inhibits R5 HIV replication in peripheral blood monocytes treated with 1-methyladenosine. Pathobiology (2005) 0.87
Expression levels of NF-Y target genes changed by CDKN1B correlate with clinical prognosis in multiple cancers. Genomics (2009) 0.87
Glycyrrhizin inhibits the manifestations of anti-inflammatory responses that appear in association with systemic inflammatory response syndrome (SIRS)-like reactions. Cytokine (2006) 0.87
The distal sequence element of the selenocysteine tRNA gene is a tissue-dependent enhancer essential for mouse embryogenesis. Mol Cell Biol (2005) 0.87
Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines. Mol Cancer Ther (2009) 0.87
Carcinogenicity of dimethylarsinic acid in Ogg1-deficient mice. Cancer Sci (2007) 0.86
Metallothionein deficiency enhances skin carcinogenesis induced by 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol-13-acetate in metallothionein-null mice. Carcinogenesis (2003) 0.86
Soluble IL-4 receptor improves the skin-graft-associated cytomegalovirus infection in thermally injured mice. Burns (2003) 0.86
Flexible metallic ultrasonic transducers for structural health monitoring of pipes at high temperatures. IEEE Trans Ultrason Ferroelectr Freq Control (2010) 0.86
CCL2, a product of mice early after systemic inflammatory response syndrome (SIRS), induces alternatively activated macrophages capable of impairing antibacterial resistance of SIRS mice. J Leukoc Biol (2004) 0.86
CCL1 released from M2b macrophages is essentially required for the maintenance of their properties. J Leukoc Biol (2012) 0.86
Appearance of monocyte chemoattractant protein 1 (MCP-1) early after thermal injury: role in the subsequent development of burn-associated type 2 T-cell responses. Ann Surg (2002) 0.86
Cdk-mediated phosphorylation of pRB regulates HDAC binding in vitro. Biochem Biophys Res Commun (2004) 0.85
The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J Invest Dermatol (2004) 0.84
Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors. Bioorg Med Chem Lett (2009) 0.84
Conophylline suppresses pancreatic stellate cells and improves islet fibrosis in Goto-Kakizaki rats. Endocrinology (2011) 0.84
Effect of glycyrrhizin, an active component of licorice roots, on HIV replication in cultures of peripheral blood mononuclear cells from HIV-seropositive patients. Pathobiology (2003) 0.84
Pathogenic role of macrophages in intradermal infection of methicillin-resistant Staphylococcus aureus in thermally injured mice. Infect Immun (2010) 0.83
Enhanced spontaneous and aflatoxin-induced liver tumorigenesis in xeroderma pigmentosum group A gene-deficient mice. Carcinogenesis (2002) 0.83
Increased norepinephrine production associated with burn injuries results in CCL2 production and type 2 T cell generation. Burns (2004) 0.83
Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. Hum Genet (2010) 0.82
Enhanced histaminergic neurotransmission and sleep-wake alterations, a study in histamine H3-receptor knock-out mice. Neuropsychopharmacology (2013) 0.82
Glycyrrhizin inhibits neutrophil-associated generation of alternatively activated macrophages. Cytokine (2006) 0.82
Insulin-like growth factor-I/insulin-like growth factor binding protein-3 alters lymphocyte responsiveness following severe burn. J Surg Res (2004) 0.82
Contribution of the sympathetic nervous system on the burn-associated impairment of CCL3 production. Cytokine (2005) 0.82
Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples. Mol Cancer (2011) 0.82
Identification of beta-catenin as a novel substrate of Polo-like kinase 1. Cell Cycle (2008) 0.82
Lithium-induced Hashimoto's encephalopathy: a case report. Bipolar Disord (2008) 0.81